Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N.

Cancers (Basel). 2019 Jul 31;11(8). pii: E1084. doi: 10.3390/cancers11081084.

2.

Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability.

Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Hepatol Res. 2019 Jul 13. doi: 10.1111/hepr.13407. [Epub ahead of print]

PMID:
31301213
3.

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M.

Cancers (Basel). 2019 Jul 7;11(7). pii: E952. doi: 10.3390/cancers11070952.

4.

Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.

Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, Kudo M.

J Med Virol. 2019 Oct;91(10):1804-1810. doi: 10.1002/jmv.25515. Epub 2019 Jul 2.

PMID:
31199513
5.

Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.

Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, Kudo M.

Antivir Ther. 2018;23(6):513-521. doi: 10.3851/IMP3225.

PMID:
29438098
6.

Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):589-597. doi: 10.1159/000480208. Epub 2017 Oct 17.

PMID:
29040992
7.

Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):583-588. doi: 10.1159/000480186. Epub 2017 Oct 17.

PMID:
29040991
8.

Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.

Ida H, Hagiwara S, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Minami Y, Ueshima K, Nishida N, Kudo M.

Dig Dis. 2017;35(6):565-573. doi: 10.1159/000480183. Epub 2017 Oct 17.

PMID:
29040989
9.

Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals.

Kono M, Nishida N, Hagiwara S, Minami T, Chishina H, Arizumi T, Minaga K, Kamata K, Komeda Y, Sakurai T, Takenaka M, Takita M, Yada N, Ida H, Minami Y, Ueshima K, Watanabe T, Kudo M.

Dig Dis. 2017;35(6):556-564. doi: 10.1159/000480148. Epub 2017 Oct 17.

PMID:
29040988
10.

Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C.

Umehara Y, Hagiwara S, Nishida N, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Chishina H, Ueshima K, Komeda Y, Arizumi T, Watanabe T, Kudo M.

Dig Dis. 2017;35(6):548-555. doi: 10.1159/000480147. Epub 2017 Oct 17.

PMID:
29040987
11.

The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.

Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Liver Cancer. 2017 Jun;6(3):227-235. doi: 10.1159/000475777. Epub 2017 May 9.

12.

Influence of Liver Inflammation on Liver Stiffness Measurement in Patients with Autoimmune Hepatitis Evaluation by Combinational Elastography.

Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Oncology. 2017;92 Suppl 1:10-15. doi: 10.1159/000451011. Epub 2017 Jan 6.

13.

Malignant Transformation of Hepatocellular Adenoma.

Kwok WY, Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Kono M, Ueshima K, Komeda Y, Arizumi T, Enoki E, Nakai T, Kumabe T, Nakashima O, Kondo F, Kudo M.

Oncology. 2017;92 Suppl 1:16-28. doi: 10.1159/000451012. Epub 2016 Dec 17.

14.

Contrast-Enhanced Tissue Harmonic Imaging versus Phase Inversion Harmonic Sonographic Imaging for the Delineation of Hepatocellular Carcinomas.

Kono M, Minami Y, Iwanishi M, Minami T, Chishina H, Arizumi T, Komeda Y, Sakurai T, Takita M, Yada N, Ida H, Hagiwara S, Ueshima K, Nishida N, Kudo M.

Oncology. 2017;92 Suppl 1:29-34. doi: 10.1159/000451014. Epub 2016 Dec 15.

15.

Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease.

Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, Kudo M.

Oncology. 2017;92 Suppl 1:3-9. doi: 10.1159/000451010. Epub 2016 Dec 15.

16.

US-US Fusion Imaging in Radiofrequency Ablation for Liver Metastases.

Minami Y, Minami T, Chishina H, Kono M, Arizumi T, Takita M, Yada N, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Dig Dis. 2016;34(6):687-691. Epub 2016 Oct 17.

PMID:
27750238
17.

Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.

Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ida H, Sakurai T, Kitano M, Nishida N, Kudo M.

Dig Dis. 2016;34(6):671-678. Epub 2016 Oct 17.

PMID:
27750236
18.

Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.

Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, Kudo M.

Dig Dis. 2016;34(6):659-664. Epub 2016 Oct 17.

PMID:
27750234
19.

Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease.

Takita M, Iwanishi M, Minami T, Kono M, Chishina H, Arizumi T, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Naoshi N, Kudo M.

Dig Dis. 2016;34(6):654-658. Epub 2016 Oct 17.

PMID:
27750233
20.

Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography.

Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Dig Dis. 2016;34(6):650-653. Epub 2016 Oct 17.

PMID:
27750232

Supplemental Content

Loading ...
Support Center